A recent study has challenged the prevailing belief that childhood trauma influences the experiences individuals have with ayahuasca, a psychoactive brew traditionally used by Indigenous cultures for spiritual and healing purposes.
Read moreOprah Has a User's Guide for Psychedelics
Oprah’s website OprahDaily.com has published a guide to psychedelics and psychedelic-assisted therapy.
Read more"The Onion" Takes on Psychedelics
Preparing for Death
F.D.A. Panel Votes Against MDMA-Assisted Therapy for PTSD
The Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted overwhelmingly to reject MDMA-assisted therapy in the treatment of post traumatic stress disorder, or PTSD.
The FDA will issue its final decision on the matter in mid-August but in the majority of cases, the federal agency’s decisions align with the vote of the independent panelists on advisory committees.
Read morePsilocybin for Anorexia
This psychiatric disorder, known for its high mortality rate, has long been a challenging condition to treat effectively.
The research, conducted at Monash University, revealed that psilocybin could improve cognitive flexibility and help maintain body weight in an animal model of AN.
Read moreMDMA Trials for PTSD Facing Setbacks?
Two articles cover this recent update.
npr: Misconduct claims may derail MDMA psychedelic treatment for PTSD
Axios: Landmark review spotlights challenge of judging psychedelic therapies
Read morePsychedelics and Prolonged Grief Disorder
Randomized clinical trials demonstrated the efficacy of psilocybin in reducing symptom severity in depression and MDMA in reducing PTSD symptomatology.
Furthermore, psychedelics often produce subjective effects (such as transcendence, mystical experiences, and a sense of oneness) that may be uniquely relevant to the existential distress experienced in PGD.
Read moreStudy: Psychedelics and the Inner Healer
Reference to an intrinsic healing mechanism or an ‘inner healer’ is commonplace amongst psychedelic users.
Read moreAyahuasca in the US
Novel 5-MeO-DMT Formulation BPL-003
Beckley Psytech Ltd, the private, clinical-stage biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing effective and rapid-acting psychedelic medicines, today announced the publication of a new paper in The Journal of Psychopharmacology which demonstrates the safety, tolerability and rapid-acting subjective effects of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT (also known as mebufotenin).
Read more